Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLC901 in Hypoxic-ischemic Brain Injury
NCT05621590Phase 1Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mlc901 in hypoxic-ischemic encephalopathy (HIE), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Glasgow Outcome Scale at 6 months and modified Rankin Scale at 6 months. Started Mar 2020; status: completed.
02
Drugs
mlc901
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT05621590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621590.